These results prompted enrolment to a second part of the phase 1/2 trial of patients with FGFR2-fusion positive metastatic or inoperable ICCA, who had either progressed after at least one line of treatment or were ineligible for chemotherapy. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.